Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
Open Access
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 10 (5) , 1212-1222
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the AdultCanadian Journal of Cardiology, 2013
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trialEuropean Heart Journal, 2012
- MipomersenCardiology in Review, 2012
- Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and CanadaEuropean Journal of Preventive Cardiology, 2011
- Achieving Optimal Lipid Goals in Patients With Coronary Artery DiseaseThe American Journal of Cardiology, 2011
- Risk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyDrug Safety, 2010
- Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)The American Journal of Cardiology, 2010
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factorClinical Science, 2008
- Model-based development of gemcabene, a new lipid-altering agentThe AAPS Journal, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJACC, 2004